A 3-day anti-Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection

Y. H. Hsieh, H. J. Lin, G. Y. Tseng, C. L. Perng, F. Y. Chang, S. D. Lee

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/Aims: One-week triple therapy has been recommended as a standard regimen for eradicating Helicobacter pylori infection. The emergence of antibiotic-resistant strains, adverse drug effects, poor compliance and high cost of therapy add problems to the management of these patients. In this study, we assessed whether a 3-day triple therapy could be effective in eradicating Helicobacter pylori infection in bleeding peptic ulcer patients. Methodology: Peptic ulcer patients with Helicobacter pylori infection were enrolled in this study. Patients enrolled at the outpatient department (group A) received a 7-day oral regimen: bismuth subcitrate colloid 300mg + amoxicillin 500mg + metronidazole 250mg four times per day. Patients who were admitted to the wards due to peptic ulcer bleeding (group B) received a 3-day regimen including omeprazole 40mg intravenously every 6 hours, amoxicillin 500mg + metronidazole 250mg orally four times daily after hemostasis had been achieved. Patients of both groups received omeprazole 20mg once per day or cimetidine 400mg twice daily per os for at least one month after anti-Helicobacter pylori therapy. We followed every patient endoscopically two months after anti-Helicobacter pylori therapy. Results: From June 1997 to April 1999, a total of 57 patients (30 in group A and 27 in group B) with gastric or duodenal ulcer and Helicobacter pylori infection completed anti-Helicobacter pylori therapy. Two months after anti-Helicobacter pylori therapy, peptic ulcer was found to be healed with a scar in 26 (86.7%) of group A and 23 (85.2%) of group B (P>0.1). The eradication rates of Helicobacter pylori in the two groups were not significantly different in an intention-to-treat analysis [group A: 78.8% (26/33), 95% CI: 64.9-92.7%; group B: 80% (24/30), 95% CI: 65.7-94.3%, P>0.1] and in a per protocol analysis [group A: 86.7% (26/30), 95% CI: 74.5-98.9%, group B: 88.9% (24/27), 95% Cl: 77.1-100.7%, P>0.1]. Fewer side effects occurred in group B (3/30) than those in group A (7/33) (P>0.1). Conclusions: In patients with peptic ulcer bleeding a 3-day anti-Helicobacter pylori therapy is a good alternative for eradicating Helicobacter pylori infection.

Original languageEnglish
Pages (from-to)1078-1081
Number of pages4
JournalHepato-Gastroenterology
Volume48
Issue number40
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Helicobacter Infections
Peptic Ulcer
Helicobacter pylori
Hemorrhage
Therapeutics
Omeprazole
Amoxicillin
Metronidazole
Intention to Treat Analysis
Cimetidine
Colloids
Stomach Ulcer
Duodenal Ulcer
Hemostasis
Cicatrix
Outpatients
Anti-Bacterial Agents
Costs and Cost Analysis

Keywords

  • Helicobacter pylori
  • Peptic ulcer bleeding
  • Triple therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A 3-day anti-Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection. / Hsieh, Y. H.; Lin, H. J.; Tseng, G. Y.; Perng, C. L.; Chang, F. Y.; Lee, S. D.

In: Hepato-Gastroenterology, Vol. 48, No. 40, 2001, p. 1078-1081.

Research output: Contribution to journalArticle

Hsieh, Y. H. ; Lin, H. J. ; Tseng, G. Y. ; Perng, C. L. ; Chang, F. Y. ; Lee, S. D. / A 3-day anti-Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection. In: Hepato-Gastroenterology. 2001 ; Vol. 48, No. 40. pp. 1078-1081.
@article{a71904feb21e4468821ecf21f7b70fc8,
title = "A 3-day anti-Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection",
abstract = "Background/Aims: One-week triple therapy has been recommended as a standard regimen for eradicating Helicobacter pylori infection. The emergence of antibiotic-resistant strains, adverse drug effects, poor compliance and high cost of therapy add problems to the management of these patients. In this study, we assessed whether a 3-day triple therapy could be effective in eradicating Helicobacter pylori infection in bleeding peptic ulcer patients. Methodology: Peptic ulcer patients with Helicobacter pylori infection were enrolled in this study. Patients enrolled at the outpatient department (group A) received a 7-day oral regimen: bismuth subcitrate colloid 300mg + amoxicillin 500mg + metronidazole 250mg four times per day. Patients who were admitted to the wards due to peptic ulcer bleeding (group B) received a 3-day regimen including omeprazole 40mg intravenously every 6 hours, amoxicillin 500mg + metronidazole 250mg orally four times daily after hemostasis had been achieved. Patients of both groups received omeprazole 20mg once per day or cimetidine 400mg twice daily per os for at least one month after anti-Helicobacter pylori therapy. We followed every patient endoscopically two months after anti-Helicobacter pylori therapy. Results: From June 1997 to April 1999, a total of 57 patients (30 in group A and 27 in group B) with gastric or duodenal ulcer and Helicobacter pylori infection completed anti-Helicobacter pylori therapy. Two months after anti-Helicobacter pylori therapy, peptic ulcer was found to be healed with a scar in 26 (86.7{\%}) of group A and 23 (85.2{\%}) of group B (P>0.1). The eradication rates of Helicobacter pylori in the two groups were not significantly different in an intention-to-treat analysis [group A: 78.8{\%} (26/33), 95{\%} CI: 64.9-92.7{\%}; group B: 80{\%} (24/30), 95{\%} CI: 65.7-94.3{\%}, P>0.1] and in a per protocol analysis [group A: 86.7{\%} (26/30), 95{\%} CI: 74.5-98.9{\%}, group B: 88.9{\%} (24/27), 95{\%} Cl: 77.1-100.7{\%}, P>0.1]. Fewer side effects occurred in group B (3/30) than those in group A (7/33) (P>0.1). Conclusions: In patients with peptic ulcer bleeding a 3-day anti-Helicobacter pylori therapy is a good alternative for eradicating Helicobacter pylori infection.",
keywords = "Helicobacter pylori, Peptic ulcer bleeding, Triple therapy",
author = "Hsieh, {Y. H.} and Lin, {H. J.} and Tseng, {G. Y.} and Perng, {C. L.} and Chang, {F. Y.} and Lee, {S. D.}",
year = "2001",
language = "English",
volume = "48",
pages = "1078--1081",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "40",

}

TY - JOUR

T1 - A 3-day anti-Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection

AU - Hsieh, Y. H.

AU - Lin, H. J.

AU - Tseng, G. Y.

AU - Perng, C. L.

AU - Chang, F. Y.

AU - Lee, S. D.

PY - 2001

Y1 - 2001

N2 - Background/Aims: One-week triple therapy has been recommended as a standard regimen for eradicating Helicobacter pylori infection. The emergence of antibiotic-resistant strains, adverse drug effects, poor compliance and high cost of therapy add problems to the management of these patients. In this study, we assessed whether a 3-day triple therapy could be effective in eradicating Helicobacter pylori infection in bleeding peptic ulcer patients. Methodology: Peptic ulcer patients with Helicobacter pylori infection were enrolled in this study. Patients enrolled at the outpatient department (group A) received a 7-day oral regimen: bismuth subcitrate colloid 300mg + amoxicillin 500mg + metronidazole 250mg four times per day. Patients who were admitted to the wards due to peptic ulcer bleeding (group B) received a 3-day regimen including omeprazole 40mg intravenously every 6 hours, amoxicillin 500mg + metronidazole 250mg orally four times daily after hemostasis had been achieved. Patients of both groups received omeprazole 20mg once per day or cimetidine 400mg twice daily per os for at least one month after anti-Helicobacter pylori therapy. We followed every patient endoscopically two months after anti-Helicobacter pylori therapy. Results: From June 1997 to April 1999, a total of 57 patients (30 in group A and 27 in group B) with gastric or duodenal ulcer and Helicobacter pylori infection completed anti-Helicobacter pylori therapy. Two months after anti-Helicobacter pylori therapy, peptic ulcer was found to be healed with a scar in 26 (86.7%) of group A and 23 (85.2%) of group B (P>0.1). The eradication rates of Helicobacter pylori in the two groups were not significantly different in an intention-to-treat analysis [group A: 78.8% (26/33), 95% CI: 64.9-92.7%; group B: 80% (24/30), 95% CI: 65.7-94.3%, P>0.1] and in a per protocol analysis [group A: 86.7% (26/30), 95% CI: 74.5-98.9%, group B: 88.9% (24/27), 95% Cl: 77.1-100.7%, P>0.1]. Fewer side effects occurred in group B (3/30) than those in group A (7/33) (P>0.1). Conclusions: In patients with peptic ulcer bleeding a 3-day anti-Helicobacter pylori therapy is a good alternative for eradicating Helicobacter pylori infection.

AB - Background/Aims: One-week triple therapy has been recommended as a standard regimen for eradicating Helicobacter pylori infection. The emergence of antibiotic-resistant strains, adverse drug effects, poor compliance and high cost of therapy add problems to the management of these patients. In this study, we assessed whether a 3-day triple therapy could be effective in eradicating Helicobacter pylori infection in bleeding peptic ulcer patients. Methodology: Peptic ulcer patients with Helicobacter pylori infection were enrolled in this study. Patients enrolled at the outpatient department (group A) received a 7-day oral regimen: bismuth subcitrate colloid 300mg + amoxicillin 500mg + metronidazole 250mg four times per day. Patients who were admitted to the wards due to peptic ulcer bleeding (group B) received a 3-day regimen including omeprazole 40mg intravenously every 6 hours, amoxicillin 500mg + metronidazole 250mg orally four times daily after hemostasis had been achieved. Patients of both groups received omeprazole 20mg once per day or cimetidine 400mg twice daily per os for at least one month after anti-Helicobacter pylori therapy. We followed every patient endoscopically two months after anti-Helicobacter pylori therapy. Results: From June 1997 to April 1999, a total of 57 patients (30 in group A and 27 in group B) with gastric or duodenal ulcer and Helicobacter pylori infection completed anti-Helicobacter pylori therapy. Two months after anti-Helicobacter pylori therapy, peptic ulcer was found to be healed with a scar in 26 (86.7%) of group A and 23 (85.2%) of group B (P>0.1). The eradication rates of Helicobacter pylori in the two groups were not significantly different in an intention-to-treat analysis [group A: 78.8% (26/33), 95% CI: 64.9-92.7%; group B: 80% (24/30), 95% CI: 65.7-94.3%, P>0.1] and in a per protocol analysis [group A: 86.7% (26/30), 95% CI: 74.5-98.9%, group B: 88.9% (24/27), 95% Cl: 77.1-100.7%, P>0.1]. Fewer side effects occurred in group B (3/30) than those in group A (7/33) (P>0.1). Conclusions: In patients with peptic ulcer bleeding a 3-day anti-Helicobacter pylori therapy is a good alternative for eradicating Helicobacter pylori infection.

KW - Helicobacter pylori

KW - Peptic ulcer bleeding

KW - Triple therapy

UR - http://www.scopus.com/inward/record.url?scp=0034886348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034886348&partnerID=8YFLogxK

M3 - Article

C2 - 11490804

AN - SCOPUS:0034886348

VL - 48

SP - 1078

EP - 1081

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 40

ER -